CoChat

Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes

Open access
Dushay, Jody, Gao, Chuanyun, Gopalakrishnan, Gosala S., Crawley, Meghan, Mitten, Emilie K., Wilker, Elissa, Mullington, Janet, Maratos-Flier, Eleftheria · 2012 · Diabetes Care
Cited by 150

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. RESEARCH DESIGN AND METHODS: Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m2) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period. There was no lifestyle intervention. The primary outcome was change in body weight. RESULTS: Subjects treated with exenatide lost an average of 2.49 ± 0.66 kg compared with a 0.43 ± 0.63 kg weight gain during placebo treatment. Weight loss with exenatide treatment was noted at 2 weeks. The degree of weight loss could be stratified. A total of 30% of subjects were high responders who lost ≥5% body weight (−7.96 ± 0.52%), 39% were moderate responders who lost <5% body weight (−2.43 ± 0.45%), and 31% were nonresponders who gained weight (1.93 ± 0.53%). Waist circumference also decreased significantly with exenatide treatment. Subjects experienced more nausea during exenatide treatment compared with placebo, but the severity decreased over time and did not correlate with weight loss. CONCLUSIONS: Short-term exenatide treatment was associated with modest weight loss and decreased waist circumference in a cohort of obese nondiabetic women. A subset of individuals demonstrated robust weight loss that was detected very early in the course of treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc11-0931

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 7

  1. Glant, 2011, Present and future: pharmacologic treatment of obesity, J Obes, 2011, 636181
  2. O’Brien, 2010, Bariatric surgery: mechanisms, indications and outcomes, J Gastroenterol Hepatol, 25, 1358, 10.1111/j.1440-1746.2010.06391.x · DOI · Paper page
  3. Tong, 2011, Is the GLP-1 system a viable therapeutic target for weight reduction?, 187
  4. Verdich, 2001, A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans, J Clin Endocrinol Metab, 86, 4382
  5. Rosenstock, 2010, Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes, Diabetes Care, 33, 1173, 10.2337/dc09-1203 · DOI · Paper page
  6. Shalev, 1997, Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man, Eur J Clin Invest, 27, 10, 10.1046/j.1365-2362.1997.540613.x · DOI
  7. Okerson, The cardiovascular effects of GLP-1 receptor agonists, 10.1111/j.1755-5922.2010.00256.x · DOI · Paper page

Cited by

See all 150

Metadata

Authors
Dushay, J., Gao, C., Gopalakrishnan, G. S., Crawley, M., Mitten, E. K., Wilker, E., Mullington, J., & Maratos-Flier, E.
Venue
Diabetes Care
Published
2011-12-09
Volume
35
Issue
1
Pages
4-11
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2070260892
Cited by
150
References
18
FWCI
10.01
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes. https://app.cochat.ai/papers/10.2337/dc11-0931
The paper
Dushay, J., Gao, C., Gopalakrishnan, G. S., Crawley, M., Mitten, E. K., Wilker, E., Mullington, J., & Maratos-Flier, E. (2012). Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes. Diabetes Care. https://doi.org/10.2337/dc11-0931

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.